Eli Lilly Expands Collaboration With Camurus

Dow Jones
Jun 02

By Kelly Cloonan

 

Eli Lilly expanded its work with Camurus, extending its rights to use one of the Swedish biopharmaceutical firm's technologies to develop and commercialize drugs.

Camurus said Monday that Lilly exercised its option to include amylin receptor agonists in the companies' collaboration and license agreement entered into in June 2025. The move expands Lilly's exclusive rights to Camurus' FluidCrystal technology for the development and commercialization of long-acting cardiometabolic drugs to an additional compound class.

Under the agreement, Camurus is eligible to receive up to $290 million in upfront development and regulatory milestone payments, as well as $580 million in sales-based milestone payments. The company is also eligible to earn tiered mid-single-digit royalties on product sales.

Lilly's move to exercise the extension option triggers a $5 million initial payment to Camurus, is subject to milestone payments and the same royalty levels as other compounds in the collaboration, Camurus said.

FluidCrystal is designed to deliver therapeutic levels of a drug over extended periods, stretching from days to months, with a single injection using a prefilled syringe or autoinjector pen. The technology has commercial and regulatory approvals in Europe, the U.S. and Australia.

 

Write to Kelly Cloonan at kelly.cloonan@wsj.com

 

(END) Dow Jones Newswires

June 01, 2026 12:26 ET (16:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10